Search form

Search form

Former Chesapeake Energy CEO Aubrey McClendon said his company American Energy Partners has made its first entry into the Permian Basin as part of a $4.3 billion agreement to lease shale properties across Texas, West Virginia and Ohio. The company plans to operate six to eight rigs in the Permian by the end of 2015 and drill nearly 2,000 wells in the basin over the next 10 years. The company now controls 63,000 acres in the basin and "intends to increase its position ... through additional acquisitions over time," the company said in a statement.

Related Summaries

A $4.354 billion turnkey engineering, procurement and construction contract has been signed by Magnolia LNG for its planned Lake Charles, La., natural gas liquefaction plant. The company also received a final Federal Energy Regulatory Commission environmental impact statement for the plant construction project and the Kinder Morgan Louisiana Pipeline Lake Charles Expansion Project.

The Federal Energy Regulatory Commission has approved a merged between NextEra Energy and Hawaiian Electric Industries valued at $4.3 billion. "We will continue to work closely with our partners at Hawaiian Electric in pursuing the remaining necessary approvals to complete the merger and begin to deliver the more affordable clean energy future we all want for Hawaii," said NextEra Chairman and CEO Jim Robo.

NextEra Energy will purchase Hawaiian Electric Industries for $4.3 billion to develop renewable energy in the state and upgrade its electric grid, according to the company. "We believe our strengths are additive to Hawaiian Electric's, creating an opportunity to enhance value for Hawaii's strategically important energy industry," said NextEra Energy Chairman and CEO Jim Robo.

Edison Pharmaceuticals and Dainippon Sumitomo Pharma will collaborate in the development of 10 new drugs that target the central nervous system's redox control energy system, which plays a role in cellular energy metabolism regulation. The partnership, which expands a March 2013 deal between the firms, could net Edison as much as $4.295 billion. "The broadening of our partnership with Edison reflects the success we have had to date in our current collaborative development programs. Compelling data suggest that the mitochondria and redox regulation play a central role in a variety of disease mechanisms," DSP official Hiroshi Noguchi said.

AstraZeneca agreed to acquire Bristol-Myers Squibb's stake in their diabetes joint venture for $2.7 billion upfront and up to $1.4 billion in potential milestone fees. Bristol, which could further receive up to $225 million if it agrees to take over certain assets, said it sees more promise in cancer, antiviral and specialty drugs. The acquisition will give AstraZeneca sole rights to several diabetes drugs, such as Onglyza and Forxiga.